Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Fatty acid binding protein 5 psoriasis-associated (FABP5; EFABP)

In vitro and mouse studies suggest FABP5 inhibition could help treat breast cancer. In mouse embryonic fibroblasts, vector-mediated overexpression of FABP5 caused oncogenic transformation and increased cell proliferation, migration and invasion compared with normal FABP5 expression. In a transgenic mouse model for epidermal growth factor receptor (EGFR)-driven breast cancer, Fabp5 knockout suppressed mammary tumor development and decreased EGFR signaling compared with no knockout. Ongoing studies include creating FABP5 inhibitors in sufficient quantities for preclinical testing.

SciBX 6(26); doi:10.1038/scibx.2013.648
Published online July 11, 2013

Patent application filed covering FABP5 inhibitors and their use in cancer; available for licensing

Levi, L. et al. Cancer Res.; published online May 30, 2013;
doi:10.1158/0008-5472.CAN-13-0384
Contact: Noa Noy, Case Western Reserve University School of Medicine, Cleveland, Ohio
e-mail:
nxn51@case.edu